Benjamin Hickey, MBA


Benjamin Hickey is a member of the Mural Oncology Board of Directors and serves as chair of the Nominating & Corporate Governance Committee.

Since March 2024, Mr. Hickey has served as president of RayzeBio, Inc., a Bristol Myers Squibb company, where he is responsible for all aspects of research, development and commercialization. He also sits on the executive leadership team of BMS, while continuing to serve as the head of Mirati Therapeutics, a BMS company. From January 2020 to March 2024, Mr. Hickey served as the executive vice president, chief commercial officer of Mirati, a commercial-stage publicly traded oncology company, where he oversaw all aspects of global commercialization, including pricing and access, sales and marketing, medical affairs, portfolio planning, patient advocacy, corporate strategy and business development.

Prior to Mirati, Mr. Hickey served as senior vice president and chief commercial officer of Halozyme Therapeutics, Inc., a publicly traded biotechnology company, responsible for global commercial strategy for the company’s oncology portfolio from September 2018 to January 2020. He spent 17 years in roles of increasing responsibility at BMS, including vice president of marketing, immuno-oncology, where he oversaw the commercialization of YERVOY® and OPDIVO®, from August 2014 to August 2016, and General Manager UK & Ireland from August 2016 to September 2018. Mr. Hickey served on the board of directors of Surface Oncology, Inc., a publicly traded clinical-stage immuno-oncology company, from December 2021 to September 2023, when it was acquired by Coherus BioSciences.

Mr. Hickey received his B.S. in Sports Management and MBA degrees from St. John’s University in New York.